Home/Guides/Hepatitis C

A Research Guide for
Hepatitis C

Hepatitis C is now curable for almost everyone — a short course of well-tolerated pills, often started by a primary care provider, sometimes in a single visit.

This guide is not medical advice. It is an educational research summary written in plain language, drawn from published medical literature, major clinical trials, and official guidelines. Every important decision must be made together with the patient’s medical team. Nothing here replaces those conversations. The purpose of this guide is to help patients and families walk into those conversations better prepared. This content does not create a doctor-patient relationship. Trouvera’s guides are produced using AI-assisted research synthesis with human editorial review; they are not written by treating physicians. Laws regarding medical information vary by jurisdiction; consult a local licensed professional for advice specific to your situation.
Standard care first. Modern direct-acting antiviral (DAA) therapy is the standard of care and cures more than 95% of people. This guide is educational and does not replace individualized advice from your own clinician. Treatment choice depends on your prior treatment, whether you have cirrhosis, your other medicines, kidney function, pregnancy, and coinfections.
Safety warning. Two safety points that change treatment: (1) The “previr” protease-inhibitor regimens (glecaprevir, voxilaprevir, grazoprevir) must not be used in decompensated cirrhosis (Child-Pugh B or C). (2) Everyone must be screened for hepatitis B before starting DAAs because of a risk of hepatitis B reactivation (FDA boxed warning). Always have every medicine and supplement reviewed for interactions — especially amiodarone with sofosbuvir.
Content last reviewed: June 2026  ·  Based on AASLD/IDSA HCV Guidance (hcvguidelines.org, living guidance, incl. 2025 Point-of-Care Test-and-Treat Algorithm); EASL Recommendations on Treatment of Hepatitis C; WHO Guidelines for the Care and Treatment of Persons with Chronic HCV (2022) and 2030 elimination strategy; USPSTF 2020 and CDC 2020 universal screening recommendations; FDA labels for Epclusa, Mavyret, Vosevi, Harvoni, Zepatier; registration trials (ASTRAL, ENDURANCE, EXPEDITION, SURVEYOR, POLARIS, ION, C-EDGE, DORA, THINKER).  ·  Always verify with your medical team.

⚡ Quick Start — If You Read Nothing Else

The 10 most important things to know right now.

  1. Hepatitis C is curable — for almost everyone. Modern pills called direct-acting antivirals (DAAs) cure more than 95% of people. A typical course is one to three pills once a day for 8 to 12 weeks, usually with few or no side effects. This is nothing like the old interferon shots that took up to a year, made people very ill, and cured fewer than half.
  2. “Cure” has a precise meaning: SVR12. If your blood has no detectable hepatitis C virus 12 weeks after you finish treatment, that is a sustained virologic response (SVR12) — considered a permanent cure. The virus does not come back on its own.
  3. Everyone should be tested at least once. The CDC and the U.S. Preventive Services Task Force recommend a one-time hepatitis C test for all adults, and a test during every pregnancy. Most people have no symptoms for decades, so testing — not symptoms — is how the infection is found.
  4. You usually don’t need genotype testing anymore. The two main regimens — sofosbuvir/velpatasvir (Epclusa) and glecaprevir/pibrentasvir (Mavyret) — are “pangenotypic,” meaning they work against all six major types of the virus. One regimen fits almost everyone.
  5. Many people can be cured by their regular doctor. Simplified treatment lets primary care clinicians — and in some clinics pharmacists or nurses — treat people who don’t have cirrhosis, with very little lab monitoring. New rapid tests can confirm active infection in about an hour, so some clinics now “test and treat” in a single visit.
  6. Active drug or alcohol use is not a reason to be denied treatment. Guidelines are explicit: you should be treated regardless of how much liver scarring you have, whether you drink, and whether you inject drugs. Sobriety is not required. People who inject drugs are excellent candidates for cure.
  7. Two safety checks happen before you start. Your clinician should test you for hepatitis B (the virus can “wake up” during treatment — an FDA warning) and review every medicine and supplement you take for interactions.
  8. One heart-rhythm drug is dangerous with these pills. Amiodarone combined with sofosbuvir can cause a dangerously slow heart rate. Tell your clinician if you take it. Also mention acid reducers (like omeprazole), statins, seizure medicines, HIV medicines, and St. John’s wort.
  9. If you already have cirrhosis, two things change. First, people with advanced (decompensated) cirrhosis must avoid the “previr” drugs and be treated at a liver center. Second, even after you’re cured, you still need an ultrasound of your liver every 6 months to screen for liver cancer, because the risk drops but does not disappear.
  10. Cure is not immunity. Being cured does not protect you from catching hepatitis C again. If you have ongoing exposure (for example, sharing injection equipment), prevention and periodic re-testing matter. There is no hepatitis C vaccine yet.
▼ Collapse

Overview: What Hepatitis C Is — and Why the Story Has Changed

Hepatitis C is an infection of the liver caused by the hepatitis C virus (HCV). It spreads when blood from an infected person enters the bloodstream of another person — most commonly today through shared needles or other injection equipment, but historically through blood transfusions (before 1992 in the U.S.), unsterile medical or dental procedures, tattooing with unsterile equipment, and, less often, from a parent to a baby during birth. It is not spread by casual contact, sharing food, hugging, or coughing.

The headline: Hepatitis C has gone from a chronic, often progressive disease treated with a year of toxic injections to a curable infection treated with 8–12 weeks of well-tolerated pills. For nearly everyone living with hepatitis C today, cure is not just possible — it is expected.

Acute vs. chronic — and why most people don’t know they have it

For the first six months after infection (“acute” hepatitis C), most people feel nothing at all. A minority — roughly a quarter to a third — clear the virus on their own without any treatment. The rest develop chronic hepatitis C, which can quietly inflame and scar the liver over years to decades. Because symptoms are usually absent until the liver is badly damaged, hepatitis C has been called a “silent” infection. That is exactly why one-time testing of all adults matters so much: it finds the infection before the damage is done.

What happens if it’s left untreated

Over many years, ongoing inflammation can cause scarring (fibrosis) that progresses through stages, sometimes ending in cirrhosis (stage F4 — heavy, permanent scarring). A liver with cirrhosis can still work for a long time (“compensated” cirrhosis), but it can also begin to fail (“decompensated” cirrhosis), and it carries an ongoing risk of liver cancer (hepatocellular carcinoma). Untreated hepatitis C is a leading cause of liver transplantation. The good news is the mirror image: finding and curing the infection before cirrhosis develops removes nearly all of this future risk.

Think of liver scarring as a one-way street that you can stop at any time — but the earlier you stop, the more the liver can recover. If you are cured before significant scarring forms, your liver-related risk afterward is close to that of someone who never had hepatitis C, and you generally will not need ongoing liver-cancer screening. If you are cured only after cirrhosis has formed, the cure still dramatically lowers your risk of liver failure, cancer, transplant, and death — but a reduced risk of liver cancer remains, so screening continues. The lesson is simple: get tested, and if positive, get treated — the sooner the better.

HCV comes in six major types (genotypes 1 through 6). Genotype 1 is most common in the U.S. and Europe; genotype 3 is common in South Asia; genotype 4 dominates Egypt and the Middle East; genotype 6 is seen in Southeast Asia and southern China. In the past, your genotype decided your treatment. Today’s pangenotypic regimens work across all of them, so for most people genotype no longer needs to be tested before starting. It may still be checked in special situations (for example, after a previous treatment didn’t work).

How this guide is organized

This guide follows the journey most people take: Screening & Diagnosis (finding out), Treatment & Cure (the pills and how they’re prescribed), Cirrhosis & Advanced Liver Disease (what changes if the liver is already scarred), After Cure & Preventing Reinfection (staying well), and Support & Resources (where to get help, including in Utah). Each section has a Questions to Ask Your Doctor list and notes for caregivers.

A note for caregivers (you’ll find more in each section): Your most valuable roles are simple and powerful — helping your person take a once-daily pill consistently for a couple of months, helping them navigate insurance approval, and treating them without judgment or stigma. Hepatitis C carries a lot of unfair shame; your steadiness matters.
  • Have I been tested for hepatitis C? If not, can we do it today?
  • If my test is positive, does that mean I have an active infection right now?
  • How much — if any — scarring does my liver have, and how will you measure it without a biopsy?
  • Am I a candidate to be treated here in your office, or do I need a specialist?
  • How soon can I start treatment?

This guide is for education and does not replace advice from your own clinician. Hepatitis C care is evolving; always confirm specifics with your treating team.

Stage 1: Screening & Diagnosis

Diagnosing hepatitis C is a short, logical sequence. Understanding it helps you ask the right questions and avoid getting “lost” between tests.

Get tested at least once, even if you feel fine. All adults should be screened once in their lifetime, and pregnant people during every pregnancy. If you have ongoing risks (such as injecting drugs), you should be tested regularly — not just once.

Step 1: The antibody test

The first test is for HCV antibodies — proteins your immune system makes after exposure to the virus. A “non-reactive” (negative) result usually means you’ve never been infected (unless you were exposed very recently). A “reactive” (positive) result means you were infected at some point — but it does not tell you whether the virus is still in your body, because antibodies remain even after the virus is gone or cured.

Step 2: The RNA (viral load) test — the one that confirms active infection

A positive antibody test should automatically trigger an HCV RNA test (also called a viral load or PCR test). This looks for the virus itself. If RNA is detected, you have an active, current infection that can be cured. If RNA is not detected, you cleared the virus (on your own or from past treatment) and don’t need treatment now.

Same-visit “test and treat” is now real. A rapid point-of-care HCV RNA test (the Cepheid Xpert HCV test) can confirm active infection in about an hour from a finger-stick or blood sample. The 2025 AASLD/IDSA guidance includes a point-of-care “test-and-treat” algorithm so that, in suitable patients, a clinic can diagnose and start the cure in the same encounter — closing the gap where people often disappear between appointments. This is especially valuable in addiction-treatment programs, emergency departments, jails and prisons, and mobile/harm-reduction settings.

Step 3: Do you need a genotype test?

Usually not. Because the standard regimens are pangenotypic, most people start treatment without ever knowing their genotype. Your clinician may order it only if the result would change your plan — for example, after a prior treatment failure.

Step 4: Checking your liver — without a biopsy

Before (or as) you start, your clinician estimates how much scarring your liver has. The key question is simply: do you have cirrhosis or not? This is now done non-invasively — liver biopsy is rarely needed:

  • Blood-test scores (FIB-4 and APRI): simple calculations using routine labs (platelets, liver enzymes, age). A low score strongly suggests little or no scarring.
  • FibroScan (transient elastography): a painless bedside ultrasound-type probe that measures liver stiffness in about 10 minutes. Higher stiffness suggests more scarring.
  • MR elastography: an MRI-based version used in some centers for added accuracy.

Step 5: Baseline labs and other screens

Before starting DAAs, expect a small panel of tests: a complete blood count, liver and kidney function, and importantly screens for hepatitis B (because of a reactivation risk — see Treatment) and HIV. People who can become pregnant are usually offered a pregnancy test and counseling, especially if a ribavirin-containing regimen is being considered.

If you have a recent, new infection, your clinician may either monitor for a few months to see whether you clear it on your own, or simply treat it — the same all-oral regimens work for acute infection. Treating early also prevents passing the virus to others. Ask which approach makes sense for you. (After a needlestick or other occupational exposure, follow your workplace’s protocol; testing is done at set intervals.)

  • Push for the confirmatory RNA test. A common failure point is stopping after a positive antibody test. Make sure the RNA test happens — ideally the same day.
  • Help collect the medication list. Bring every prescription, over-the-counter product, vitamin, and herbal supplement (including the bottles) to the visit. This speeds the interaction check.
  • Watch for stigma — including self-stigma. A hepatitis C diagnosis can bring shame that has nothing to do with reality. Reassure your person that this is a treatable medical condition, full stop.
  • Ask about same-visit treatment. If your clinic offers point-of-care testing, treatment may be able to start immediately.
  • My antibody test was positive — what was my RNA (viral load) result? Do I have an active infection?
  • What is my genotype, and does it change anything for me?
  • Do I have cirrhosis? How are you measuring my liver scarring — FIB-4, FibroScan, or something else?
  • Have you checked me for hepatitis B and HIV before I start treatment?
  • Can I be diagnosed and start treatment in the same visit here?
  • Who will explain my results and the plan, and how do I reach them with questions?

Stage 2: Treatment & Cure

This is the heart of the good news. The medicines are simple, short, and highly effective, and most people tolerate them easily.

What “cured” means. The goal is SVR12 — no detectable virus 12 weeks after your last pill. Achieving SVR12 means the infection is gone and will not return on its own. More than 95% of people reach it with first-line therapy.

The two first-line pills (pangenotypic — work against all genotypes)

  • Sofosbuvir/velpatasvir (Epclusa) — one pill once daily, usually for 12 weeks. Each tablet contains sofosbuvir 400 mg / velpatasvir 100 mg (FDA label). Can be taken with or without food. Cures all genotypes; in its main trial (ASTRAL-1) the cure rate was about 99%.
  • Glecaprevir/pibrentasvir (Mavyret) — three pills once daily with food (each tablet is glecaprevir 100 mg / pibrentasvir 40 mg, so the three-tablet dose totals 300 mg / 120 mg per day, per the FDA label), for just 8 weeks in treatment-naive people without cirrhosis (and for treatment-naive people with compensated cirrhosis, 8 weeks is also approved). Some other situations call for 12 or 16 weeks. Cure rates are consistently above 95%.

Both are taken at home. Which one you get often depends on your other medicines, your kidney function, whether you have cirrhosis, and what your insurance covers. They are equally good choices for most people; your clinician will match the regimen to you.

Dosing reference card — the exact pills and amounts

These are the standard adult doses taken from the U.S. FDA labels (prescribing information). They are here so you can double-check what you were prescribed and ask good questions — never change a dose on your own.

  • Epclusa (sofosbuvir/velpatasvir): one tablet of sofosbuvir 400 mg / velpatasvir 100 mg once daily, with or without food, usually for 12 weeks (FDA label; approved 2016).
  • Mavyret (glecaprevir/pibrentasvir): three tablets once daily with food; each tablet is glecaprevir 100 mg / pibrentasvir 40 mg, so the daily dose is 300 mg / 120 mg; 8 weeks for most treatment-naive people (FDA label; approved 2017). Children use a lower-strength pellet packet (glecaprevir 50 mg / pibrentasvir 20 mg).
  • Vosevi (salvage, if a first course fails): one tablet of sofosbuvir 400 mg / velpatasvir 100 mg / voxilaprevir 100 mg once daily for 12 weeks (FDA label; approved 2017).
  • Harvoni (legacy): ledipasvir 90 mg / sofosbuvir 400 mg once daily (FDA label; approved 2014).
  • Zepatier (legacy): elbasvir 50 mg / grazoprevir 100 mg once daily (FDA label; approved 2016).
  • Ribavirin (an older add-on for a few hard cases): weight-based, roughly 1000 mg per day if you weigh under 75 kg and 1200 mg per day at or above 75 kg (200 mg tablets), split morning and evening; sometimes started lower at 600 mg per day in cirrhosis. Never used in pregnancy.
  • If your hepatitis B needs treating at the same time: tenofovir 300 mg once daily or entecavir 0.5 mg once daily (per the hepatitis B FDA labels).
  • Acid reducers, if you truly need one: with Epclusa, omeprazole should be no more than 20 mg taken together with the Epclusa dose and food; famotidine up to 40 mg twice daily is generally acceptable.
Why two drugs in one pill? Each regimen combines medicines that block the virus at different steps (for example, one blocks the NS5B copying enzyme and the other the NS5A protein). That combination is far more powerful together than either alone — a genuine synergy — and it makes it very hard for the virus to become resistant. That combined effect is a big reason cure rates jumped from under half (interferon era) to above 95%.

Children can be cured too — weight-based pediatric doses

Both first-line regimens are FDA-approved down to age 3, using weight-based amounts (per the pediatric FDA labels). If your child is being treated, these are the standard doses to expect:

  • Mavyret (pediatric pellets or tablets), once daily with food: 12 to under 20 kg → glecaprevir 150 mg / pibrentasvir 60 mg; 20 to under 30 kg → 200 mg / 80 mg; 30 to under 45 kg → 250 mg / 100 mg; 45 kg and above → the adult 300 mg / 120 mg.
  • Epclusa (pediatric pellets or tablets), once daily: under 17 kg → sofosbuvir 150 mg / velpatasvir 37.5 mg; 17 to under 30 kg → 200 mg / 50 mg; 30 kg and above → the adult 400 mg / 100 mg.
  • Liver protection during care: if not already immune, the hepatitis A and hepatitis B vaccine series are recommended; a standard adult hepatitis B vaccine dose is 10 mcg or 20 mcg depending on the product.
What to say at your appointment — word for word. Bring these questions with you:
  • Ask your doctor: "Given my other medicines and whether I have cirrhosis, is Epclusa or Mavyret the better fit for me — and is my course 8 or 12 weeks?"
  • Ask your doctor: "Have you tested me for hepatitis B before I start? The FDA requires that check because these pills can reactivate it."
  • Ask your doctor: "Do I have cirrhosis, and if so is it compensated or decompensated — does that rule out the 'previr' drugs for me?"
  • Ask your doctor: "What is the exact calendar date of my SVR12 test — the blood test 12 weeks after my last pill that confirms I'm cured?"
  • Ask your doctor: "Can you connect me with Gilead Support Path or the Mavyret Savings Card so I pay a copay, not the list price?"
Your cure timeline — what happens when.
  • Week 0 (diagnosis visit): confirm active infection with an RNA test; get screened for hepatitis B and HIV; have every medicine and supplement reviewed; check whether you have cirrhosis (FIB-4 or FibroScan).
  • Within the first week: your hepatitis B results and drug-interaction check should be back, your regimen chosen, and—for most people—treatment started, sometimes the same day.
  • First 48 hours (only if you take amiodarone): the FDA label calls for in-hospital heart-rhythm monitoring, because amiodarone plus sofosbuvir can slow the heart dangerously.
  • In the first month: take the pill every day; call the clinic (do not stop on your own) if you feel unwell.
  • By month 2 or 3: finish the full 8- or 12-week course.
  • 12 weeks after your last pill: the SVR12 blood test — an undetectable result means you are cured.
  • Every 6 months after cure (only if you had cirrhosis): a liver ultrasound to screen for liver cancer, continuing for life.

Simplified treatment — you may not need a specialist

If you are treatment-naive, not pregnant, have no prior DAA failure, and either have no cirrhosis or have compensated cirrhosis without complications, you likely qualify for the simplified treatment pathway. That means your primary care provider can prescribe one of the two regimens with minimal monitoring — often no on-treatment viral load checks at all — and confirm your cure with a single test 12 weeks after you finish.

You should be offered treatment regardless of fibrosis stage, alcohol use, or drug use. Guidelines have removed sobriety and “wait until you’re sicker’ requirements. If you are told you must be sober or must have advanced scarring to qualify, ask why — and consider a second opinion or a specialist clinic that follows current guidance.

If the first course doesn’t work: salvage therapy

For the small number of people whose first DAA course fails, sofosbuvir/velpatasvir/voxilaprevir (Vosevi) — one pill daily for 12 weeks — cures the large majority. The decision considers your prior regimen, any resistance, and whether you have cirrhosis, and is usually made with a specialist.

Ledipasvir/sofosbuvir (Harvoni) (for genotypes 1, 4, 5, 6) and elbasvir/grazoprevir (Zepatier) (for genotypes 1 and 4) are still effective and are used in some settings or for specific situations, but the pangenotypic regimens above are first-line for most people now.

Some people with decompensated cirrhosis or a previous treatment failure receive ribavirin alongside a DAA. Ribavirin can cause anemia (low red blood cells), so blood counts are watched. Critically, ribavirin can cause severe birth defects: it is strictly forbidden in pregnancy and requires reliable contraception in the patient and in female partners of male patients during and for a period after treatment.

Side effects — usually mild

Most people feel fine. The most common complaints with the pangenotypic regimens are mild headache, fatigue, and nausea. Serious side effects are uncommon. This is a world away from the interferon era. If something feels wrong, call your clinician rather than stopping on your own.

Drug interactions — the most important safety topic

Tell your clinician about every medicine and supplement before you start. Key interactions:
  • Amiodarone (a heart-rhythm drug) + sofosbuvir can cause a dangerously slow heartbeat. This combination is generally avoided.
  • Acid reducers — proton-pump inhibitors (omeprazole, esomeprazole, pantoprazole) and antacids — can lower the absorption of velpatasvir and ledipasvir. They may need to be reduced, timed differently, or paused. Don’t just stop a prescribed PPI without guidance.
  • Statins (cholesterol drugs) may need a lower dose or a temporary hold with some regimens.
  • Certain seizure medicines (carbamazepine, phenytoin), rifampin (an antibiotic), and St. John’s wort (an herbal product) can lower DAA levels and cause treatment to fail.
  • Some HIV medicines interact with DAAs and may need adjusting.
Your clinician can check any combination using the University of Liverpool HEP Drug Interaction Checker (hep-druginteractions.org).
Is there ever a reason to stop the pills early? Unlike the old interferon treatment, modern DAAs have no routine stop rule for most people — you simply finish the course. But two safety stops are written into the FDA label: your clinician will discontinue if signs of liver failure (new jaundice, fluid buildup in the belly, or confusion) appear on a “previr”-containing regimen such as Mavyret, and will know when to stop and get emergency care if amiodarone triggers a dangerously slow heartbeat. These events are rare, which is exactly why the pre-treatment hepatitis B and drug-interaction checks matter.

The few clear stop rules — what would make a clinician halt treatment

You will almost certainly finish your whole course. But it helps to know the specific safety triggers, so nothing is a surprise:

  • Discontinue if you develop signs of liver failure — new yellowing (jaundice), fluid buildup in the belly, or confusion — while taking a “previr” regimen such as Mavyret. This is a hard stop rule written into the FDA label.
  • Know when to stop and get emergency care if amiodarone plus sofosbuvir triggers a very slow heartbeat (fainting, near-fainting, severe dizziness, or a pulse that feels far too slow).
  • Discontinue if a serious allergic reaction occurs (rare) — rash with swelling or trouble breathing.
  • Unlike the old interferon era, there is no routine “trial period” and no on-treatment viral-load stop rule for standard DAA therapy — you do not stop just because you feel better; you finish the course.

Cost and patient-assistance — don’t let price stop you

List prices were historically high, but they have fallen, and most people pay far less through insurance, Medicaid, the VA, or manufacturer programs. Gilead (Epclusa) and AbbVie (Mavyret) both run patient-assistance and copay programs for eligible patients. Generic versions of some regimens also exist. If you hit a wall, ask the clinic’s pharmacist, social worker, or a patient navigator — getting these drugs approved is a routine part of their job.

What it actually costs (U.S., as of July 2026). The list (“sticker”) prices are high, but almost no one pays them:
  • Epclusa has a list price (wholesale acquisition cost) of $24,920 per 28-day bottle (Gilead, as of Jan 1, 2026) — roughly $74,760 for a 12-week course (three bottles). Gilead’s own authorized generic (made by Asegua) launched at a list price of $24,000 for the full course.
  • Mavyret has a list price of $13,200 per month (AbbVie, as of Jan 2025) — about $26,400 for the 8-week course.
  • Assistance brings this down steeply. With commercial insurance, eligible patients can pay as little as $5 per month through Gilead Support Path (1-855-769-7284) or the MAVYRET Savings Card (MAVYRET Patient Support, 1-877-628-9738). Most Medicaid patients pay $0 for the full course, and both companies offer help for the uninsured.
Have the clinic’s pharmacist or navigator start this paperwork on day one.

Costs and coverage at a glance (U.S., as of July 2026)

  • Epclusa list price (wholesale acquisition cost): $24,920 per 28-day bottle, about $74,760 for a 12-week course (Gilead, Jan 1 2026).
  • Gilead’s authorized generic (made by Asegua): about $24,000 for the full course.
  • Mavyret list price: $13,200 per month, about $26,400 for an 8-week course (AbbVie, Jan 2025).
  • Vosevi (salvage) list price is similar to Epclusa, roughly $74,760 for a 12-week course.
  • Harvoni (legacy) launched near $94,500 for 12 weeks in 2014; generic ledipasvir/sofosbuvir now costs far less.
  • Zepatier (legacy) launched near $54,600 for 12 weeks in 2016.
  • Sovaldi (sofosbuvir alone, 2013) is the drug that set off the “$1,000-a-pill” headlines at about $84,000 for 12 weeks — useful history, but not how anyone is treated today.
  • With commercial insurance: a copay as low as $5 per month through Gilead Support Path (1-855-769-7284) or the MAVYRET Savings Card (1-877-628-9738).
  • Most Medicaid patients: $0 for the full course.
  • Medicare Part D: a new $2,000 annual out-of-pocket cap took effect in 2025 (Inflation Reduction Act), which limits what any Part D patient pays in a year.
  • Global generics: licensed generic sofosbuvir/velpatasvir has sold for roughly $60 to $300 for an entire course in many low- and middle-income countries.
  • Syringe service programs: sterile injecting supplies are provided free ($0).

The single most important cost fact: with an authorized generic near $24,000, Medicaid at $0, copay cards at $5 a month, and a Medicare cap of $2,000 a year, price is no longer a valid reason to go untreated. If cost is quoted as a barrier, ask for a patient navigator.

What treatment is actually like, day to day

For most people, life barely changes during the 8–12 weeks. You take your pill (or pills) once a day, go about your normal routine, and feel essentially the same as before. You do not need to stop working, stay home, or avoid other people. There are no injections and no need to isolate. The virus is not spread by everyday contact, so you can hug your family, share meals, and live normally — just don’t share anything that might carry blood (razors, toothbrushes).

  • A missed dose is not a disaster. If you remember the same day, take it. If it’s nearly time for the next one, skip the missed dose and continue — don’t double up. Tell your clinic if you miss several days in a row.
  • Finish the whole course even when you feel completely fine (you may feel fine the whole time). Stopping early is the main avoidable reason treatment fails.
  • Mavyret must be taken with food; Epclusa can be taken with or without food. Pairing the pills with a regular meal makes both the timing and (for Mavyret) the food requirement automatic.
  • If you vomit shortly after a dose, ask your pharmacist whether to re-dose — don’t guess.
  • Don’t start any new medicine or supplement mid-treatment (including a new acid reducer, antibiotic, or herbal product) without checking it’s safe with your DAA.

What monitoring (if any) to expect

If you’re on the simplified pathway without cirrhosis, you may have no blood tests at all during treatment — just the one test 12 weeks after you finish to confirm cure (SVR12). Some people (for example, those on warfarin, those with diabetes, or those with cirrhosis) have a few checks along the way. Your clinician will tell you your specific schedule. The key appointment to protect is the SVR12 test — that’s the one that confirms you’re cured.

Liver-protective steps during and after treatment

  • Avoid alcohol (it adds injury and can blunt recovery).
  • Get vaccinated against hepatitis A and hepatitis B if you’re not already immune.
  • Work on weight and metabolic health to limit fatty-liver injury.
  • Review all medicines and herbal products for liver safety with your clinician or pharmacist.
  • Make the once-daily pill effortless. Tie it to an existing habit (morning coffee, brushing teeth), set a phone alarm, or use a weekly pill organizer. For Mavyret, remember it’s taken with food — pair it with a meal.
  • Help with the insurance maze. Prior authorization, pharmacy transfers, and assistance-program paperwork are the most common reasons treatment stalls. Offer to make calls or sit in on them.
  • Keep the full medicine list current. If a new prescription is added during treatment (antibiotic, acid reducer, statin), make sure the prescriber knows the person is on a DAA.
  • Encourage, don’t police. A missed dose now and then is not a catastrophe — just resume. Shame and pressure backfire. Steady, kind reminders win.
  • Mark the SVR12 date. Put the “12 weeks after the last pill” blood test on the calendar — that’s the test that confirms cure.
  • Which regimen is right for me — Epclusa or Mavyret — and for how long (8 vs 12 weeks)? Why that one?
  • Can my primary care provider treat me, or do I need a specialist?
  • What does SVR12 mean for me, and when exactly is the test that confirms my cure?
  • Have you reviewed all my medicines and supplements — including my acid reducer, statin, and any heart medicine like amiodarone?
  • What side effects should I expect, and when should I call you?
  • What will this cost me, and can you help me with patient-assistance or copay programs?
  • What happens if treatment doesn’t work the first time?
  • Do I need any monitoring during treatment, or just the cure test at the end?
  • What should I do if I miss a dose or accidentally skip a day?
  • If I’m prescribed a new medicine during treatment, who should I check with first?

Stage 3: Cirrhosis & Advanced Liver Disease

If your liver already has heavy scarring, you can still be cured — but a few things change about how you’re treated and what care continues afterward. This section is also written so caregivers can recognize the danger signs that require urgent help.

Compensated vs. decompensated cirrhosis

Compensated cirrhosis means the liver is scarred but still doing its jobs; many people feel well and have normal daily life. Decompensated cirrhosis means the liver is starting to fail, producing complications such as fluid buildup in the belly (ascites), confusion (hepatic encephalopathy), or internal bleeding from swollen veins (variceal bleeding). The distinction is crucial because it changes which medicines are safe.

Safety-critical: If you have decompensated cirrhosis (doctors may call this Child-Pugh B or C), you must not take the “previr” protease-inhibitor drugs — glecaprevir (in Mavyret), voxilaprevir (in Vosevi), or grazoprevir (in Zepatier) — because they can be harmful to a failing liver. Instead you’ll be treated with a sofosbuvir-based regimen (such as sofosbuvir/velpatasvir), often with ribavirin added, ideally at a liver center.

Treating cirrhosis: still very curable

People with compensated cirrhosis are cured at rates similar to everyone else and are eligible for the simplified pathway (with a cirrhosis-appropriate plan). People with decompensated cirrhosis are also frequently cured, with the protease-inhibitor-free regimens above; their care is coordinated by a hepatologist and often a transplant team.

Compensated cirrhosis often comes with few or no symptoms. Many people work, travel, and live normally for years; the scarring is there, but the liver is still keeping up. The main changes to your care are regular monitoring (a liver ultrasound every 6 months and, often, a one-time look for swollen veins in the esophagus).

Decompensated cirrhosis means the liver has started to fall behind, producing visible problems — fluid in the belly (ascites), confusion (encephalopathy), yellowing (jaundice), or bleeding from swollen veins. This stage needs specialist (hepatologist) care, a carefully chosen medication regimen, and usually a conversation about transplant. Importantly, curing the virus at this stage can sometimes improve liver function — occasionally enough that a transplant is no longer needed.

  • Liver ultrasound every 6 months (sometimes with a blood test called AFP) to catch liver cancer early.
  • An upper endoscopy (a camera down the throat) at some point to check for swollen veins (varices) that could bleed; if found, there are medicines or procedures to lower the risk.
  • Periodic blood tests (liver function, blood counts, kidney function, clotting) to track how the liver is doing.
  • Your team may calculate a score (such as MELD) that summarizes liver function and helps decide timing of treatment and, if needed, transplant.

Liver transplant — when it’s needed

For end-stage liver disease or for liver cancer that can’t be controlled other ways, a liver transplant can be life-saving. Hepatitis C is no longer a barrier: it can be cured before or after transplant. Curing the virus sometimes improves liver function enough that transplant is no longer needed; in other cases it’s cured after transplant. Transplant centers can also now safely use organs from hepatitis-C-positive donors for recipients (curing them afterward), which has expanded the donor pool and shortened waits.

If transplant is on the table, expect an evaluation phase: many appointments and tests to confirm you’re a candidate and to place you on the waiting list. Waiting times vary. Accepting an organ from a hepatitis-C-positive donor (and being cured afterward) can shorten your wait — your team will explain this option and its now-very-low risks. After transplant, the most important job is taking anti-rejection medicines exactly as prescribed, every day, for life, and keeping every follow-up. A caregiver who helps track medicines and appointments makes a real difference here.

Liver-cancer screening — before and after cure

If you have cirrhosis or advanced scarring, you need an ultrasound of your liver every 6 months (sometimes with a blood test called AFP) to catch liver cancer early — and this continues even after you’re cured. Cure lowers cancer risk substantially but does not erase it. People cured before developing significant scarring generally do not need ongoing screening.
Red flags — call 911 or get emergency care:
  • Vomiting blood or passing black, tarry stools (possible variceal bleeding).
  • New or worsening confusion, drowsiness, slurred speech, or disorientation (possible hepatic encephalopathy).
  • Rapid abdominal swelling, severe belly pain, or fever (possible infected ascites).
  • Yellowing of the eyes/skin that is rapidly worsening, or sudden severe weakness.
  • Learn the encephalopathy signs. Subtle confusion, reversed sleep–wake cycle, a flapping hand tremor, or personality change can be early. Know the medicines (such as lactulose) prescribed to prevent it, and help with the dosing schedule.
  • Track the belly. Sudden swelling, weight gain, or abdominal pain with fever warrants a same-day call.
  • Keep the 6-month liver ultrasound on the calendar — before and after cure if cirrhosis is present. This is one of the most important things you can do.
  • Support the transplant evaluation. If transplant is on the table, there are many appointments and a lot of paperwork; a second set of ears and hands is invaluable.
  • Caring for someone before or after a transplant means medication adherence (anti-rejection drugs are non-negotiable), infection vigilance, and keeping every follow-up. Ask the transplant team for their written caregiver instructions.
  • Do I have cirrhosis, and is it compensated or decompensated?
  • Given my liver, which regimen is safe for me — and which drugs must I avoid?
  • Should I be treated at a liver/transplant center?
  • Do I need to be evaluated for a liver transplant now or later?
  • How often do I need liver-cancer screening, and will that continue after I’m cured?
  • Do I need to be checked for swollen veins (varices) in my esophagus?
  • What symptoms mean I should call you, and which mean I should call 911?
  • If transplant might be needed, what does the evaluation involve, and would accepting a hepatitis-C-positive donor organ shorten my wait?
  • What is my MELD (or other liver) score, and how does it affect my treatment timing?

Stage 4: After Cure & Preventing Reinfection

Reaching SVR12 is a real milestone — the virus is gone. This section covers what cure does (and doesn’t) protect you from, and how to stay well.

Cure changes your future. Clearing the virus halts ongoing liver damage, lets some scarring partially heal over time, and sharply lowers the risk of liver failure, liver cancer, transplant, and death. People treated before cirrhosis essentially return to a normal liver-risk life.

Cure is not immunity — reinfection is possible

Being cured does not make you immune. If you’re exposed to infected blood again — most commonly by sharing injection or drug-preparation equipment — you can get hepatitis C again. This is not a moral failing or a sign the cure “didn’t work”; it’s a new, separate infection that can be cured again. The goal is to lower the chance of it happening.

How to avoid getting hepatitis C again

  • Never share injection equipment — needles, syringes, cookers, cotton, water, or ties. Use new sterile supplies every time (syringe service programs provide them free).
  • Consider medication for opioid use disorder (such as buprenorphine or methadone) if relevant — it dramatically reduces injection-related risk and is fully compatible with HCV cure.
  • Don’t share items that may carry blood — razors, toothbrushes, glucose-monitoring lancets.
  • Choose licensed, sterile tattoo and piercing providers.
  • If you have ongoing exposure, get re-tested periodically with an RNA (viral load) test — antibodies stay positive after cure, so only the RNA test detects a new infection.

Continued liver-cancer screening (only if you had cirrhosis/advanced scarring)

If you had cirrhosis or advanced fibrosis before cure, keep up the every-6-month liver ultrasound (with or without AFP). If you were cured before significant scarring, ongoing screening generally isn’t needed — ask your clinician which group you’re in.

This depends on whether you have ongoing exposure:

  • No ongoing risk (no injecting, no new exposures): you generally don’t need routine hepatitis C re-testing after cure.
  • Ongoing risk (for example, you still inject sometimes, or you’re in a setting with exposure): you should have an HCV RNA (viral load) test at least once a year, and sooner if you have a new exposure or a clinician notices a change in your liver blood tests.
  • Always the RNA test, never the antibody test, to check for a new infection — your antibody test will stay positive for life and can’t tell old from new.

If a new infection is found, it’s simply treated again with the same kind of pills. Getting reinfected is a medical event, not a personal failure.

Reaching SVR12 means the virus is gone for good (it doesn’t come back on its own). Over the following months and years, ongoing liver damage stops, and some scarring can partially heal. Your risk of liver failure, the need for a transplant, and death from liver disease all drop substantially. If you were cured before serious scarring, your liver-related outlook is close to that of someone who never had hepatitis C. If you already had cirrhosis, you’re much better off cured — but you keep the 6-month liver-cancer screening because some risk remains. Many problems hepatitis C can cause outside the liver (certain skin, kidney, nerve, and blood-vessel conditions) often improve after cure, too.

Other long-term wellness

  • Stay vaccinated against hepatitis A and B if you’re not immune.
  • Limit or avoid alcohol; manage weight, blood sugar, and cholesterol to protect the liver from fatty-liver injury.
  • Some problems caused by chronic HCV outside the liver — such as certain skin, kidney, or nerve conditions, and a type of blood-vessel inflammation called cryoglobulinemia — often improve after cure.
  • Tell future clinicians you were treated for and cured of hepatitis C; your antibody test will remain positive for life.
There is no hepatitis C vaccine yet. Because the virus mutates quickly, a preventive vaccine has been hard to make and none is approved. Research continues. For now, prevention relies on safe equipment, treatment-as-prevention (curing people reduces spread), and harm reduction.
  • Celebrate the SVR12. It’s a genuine win — acknowledge it.
  • Support harm reduction without judgment. If your loved one injects drugs, connecting them to a syringe service program and to addiction treatment is one of the most protective things you can do. Stigma drives people away from care; acceptance keeps them in it.
  • Keep the screening rhythm if cirrhosis is present — the 6-month ultrasound matters for life.
  • Normalize periodic re-testing for anyone with ongoing exposure. Reinfection is a medical event, not a character verdict.
  • Am I officially cured (did I reach SVR12)?
  • Do I still need liver-cancer screening — and for how long?
  • Given my situation, how do I avoid getting hepatitis C again, and how often should I be re-tested?
  • Am I immune to hepatitis A and B, or do I need those vaccines?
  • Will my antibody test always be positive now? What should I tell future doctors?
  • Given my situation, exactly how often should I get an RNA (viral load) test to check for a new infection?
  • If I have ongoing drug use, can you connect me with harm-reduction and treatment services?

Support & Resources

This section pulls together caregiver guidance, where to get care (with a focus on Utah and the Mountain West), how to find clinical trials, what treatments have not worked, how access differs around the world, a glossary, and the key sources behind this guide.

For caregivers — your toolkit

The four things that help most: (1) help with daily pill adherence over the 8–12 weeks; (2) help navigating insurance prior authorization and patient-assistance programs; (3) treating your person without stigma; and (4) keeping the right follow-up — the SVR12 cure test for everyone, and the 6-month liver-cancer ultrasound for anyone with cirrhosis.
  • Adherence: alarms, pill organizers, habit-stacking; remember Mavyret is taken with food.
  • Insurance/access: lean on the clinic pharmacist, social worker, or patient navigator; use Gilead and AbbVie assistance programs.
  • Stigma: language matters — “a person who injects drugs,” not “an addict”; “a person with hepatitis C,” not “infected.”
  • Advanced disease: learn encephalopathy and bleeding red flags (see Cirrhosis section); keep emergency numbers handy.
  • Harm reduction: support syringe services and addiction treatment without judgment.
  • Transplant: request the team’s written caregiver instructions; anti-rejection medicines are non-negotiable.

Word for word — what to say and ask at every step

You do not have to be a medical expert to get excellent care — you just have to ask a few precise questions. Copy these, bring them on your phone, and use the ones that fit your situation. They are written to equip you for the conversation, not to replace your clinician’s advice.

  • Ask your doctor: "Can I be tested for hepatitis C today, with an automatic RNA (viral load) test if the antibody comes back positive?"
  • Ask your doctor: "Do I have an active infection right now — was my HCV RNA actually detected?"
  • Ask your doctor: "Do I have cirrhosis, and how did you measure my liver scarring — FIB-4, FibroScan, or something else?"
  • Ask your doctor: "Have you screened me for hepatitis B (HBsAg and anti-HBc) before I start, because the FDA warns these pills can reactivate it?"
  • Ask your doctor: "Is Epclusa or Mavyret the better fit given my other medicines — and is my course 8 or 12 weeks?"
  • Ask your pharmacist: "Do any of my current medicines or supplements interact with this regimen?"
  • Ask your doctor: "I take a heart-rhythm drug — is it amiodarone, and is that dangerous with sofosbuvir?"
  • Ask your pharmacist: "Can I keep taking my acid reducer, or do I need to change the dose or timing during treatment?"
  • Ask your clinician: "Can my primary-care provider treat me, or do I need a liver specialist?"
  • Ask the clinic: "Can you enroll me in Gilead Support Path or the MAVYRET Savings Card so I pay a copay, not the list price?"
  • Ask your doctor: "What is the exact date of my SVR12 test — the blood test 12 weeks after my last pill that confirms I am cured?"
  • Ask your doctor: "If I have cirrhosis, will I still need a liver-cancer ultrasound every 6 months even after I am cured?"
  • Ask your nurse: "What should I do if I miss a dose, or if I vomit soon after taking it?"
  • Ask your doctor: "If this first course does not cure me, what is the next step — is it Vosevi?"
  • Ask your clinician: "I still inject sometimes — can you connect me with sterile supplies and treatment, and how often should I be re-tested with an RNA test?"
  • Ask your doctor: "Am I immune to hepatitis A and B, or do I need those vaccines to protect my liver?"

Specialty Center Directory

Phone numbers and programs change; please verify before relying on them. Listing here is informational, not an endorsement.

Mountain West & Utah

  • University of Utah Health — Hepatology / Liver Center (Salt Lake City). Evaluation and DAA treatment, non-invasive fibrosis staging (FibroScan), cirrhosis and portal-hypertension care, liver-cancer surveillance, and liver transplant evaluation (the regional transplant center, including protocols using hepatitis-C-positive donor organs). Main line: 801-581-2121; transplant program: 801-581-2879.
  • Intermountain Health — Gastroenterology/Hepatology (Wasatch Front & southern Utah). Hepatitis C testing and treatment, including primary-care-based simplified treatment. Find a provider via Intermountain’s main scheduling: 801-442-3000.
  • Utah Department of Health and Human Services — Viral Hepatitis Program. Testing resources, linkage-to-care, and information on Utah’s hepatitis C elimination efforts. General DHHS line: 801-538-6191.
  • Utah Naloxone & local syringe service / harm-reduction programs. Sterile supplies, naloxone, linkage to addiction treatment (opioid agonist therapy), and judgment-free hepatitis C testing and treatment. Utah Naloxone: utahnaloxone.org.
  • VA Salt Lake City Health Care System (George E. Wahlen VA Medical Center). Veterans can be screened and treated through VA hepatology and primary care — the VA has been a national leader in HCV elimination. Main line: 801-582-1565.

U.S. National Centers of Excellence

  • Johns Hopkins (Baltimore) — viral hepatitis, HIV/HCV coinfection, and HCV-positive-donor transplant research.
  • University of Pennsylvania (Philadelphia) — hepatology and the THINKER HCV-positive-donor transplant program.
  • UW Medicine / Hepatitis C Online (Seattle) — clinical care plus the widely used free education resource at hepatitisc.uw.edu.
  • Mayo Clinic (Rochester, Phoenix, Jacksonville) and Cleveland Clinic — comprehensive hepatology and transplant.
  • UCSF (San Francisco) — hepatology, PWID-focused models, and elimination research.

Veterans

  • The VA screens and treats hepatitis C system-wide and has cured a very large number of veterans. Ask your VA primary care team or hepatology clinic. Hepatitis C related to certain service exposures may be relevant to VA benefits — ask a Veterans Service Officer about service connection.

Canada

  • Toronto Centre for Liver Disease (University Health Network), University of Calgary Liver Unit, and CHUM (Montréal) are major centers. DAAs are covered through provincial and territorial drug plans (coverage details vary by province); the CADTH process informs reimbursement.

International

  • Egypt — National Committee for the Control of Viral Hepatitis (the “100 Million Healthy Lives” program) for screen-and-treat at national scale.
  • Georgia (country) — national HCV elimination program (the world’s first, launched 2015).
  • Specialist liver centers affiliated with EASL across Europe, and national hepatitis programs in Australia (an elimination leader) and elsewhere.

Clinical Trials — how to find them

The DAA cure is so effective that most current research focuses on delivering the cure (test-and-treat models, treatment in pregnancy, expanding 8-week therapy, organs from HCV-positive donors) and on a future vaccine, rather than on new pills for typical infection.

  • ClinicalTrials.gov — search “hepatitis C” and filter by “recruiting” and your location.
  • Examples of real, completed landmark studies you may see referenced: the registration trials ASTRAL-1 (NCT02201940) and ENDURANCE-1 (NCT02604017); the salvage trials POLARIS-1/4 (NCT02607735 / NCT02639247); the minimal-monitoring MINMON study (ACTG A5360); the pediatric DORA study (NCT03067129); and the HCV-positive-donor kidney transplant trial THINKER (NCT02743897). (See the clinical companion guide for a full audited list.)
  • Ask the University of Utah Hepatology program or the VA whether any active study fits your situation.

The landmark studies behind today’s cure — verified on ClinicalTrials.gov (as of July 2026)

Every identifier below was checked against the ClinicalTrials.gov record and its published result. You do not need to read these; they are here so you (or a skeptical family member) can confirm that the cure claims in this guide rest on real, completed trials.

  • ASTRAL-1 (NCT02201940) — Epclusa for 12 weeks cured about 99% of people across genotypes (Feld et al, NEJM 2015).
  • ASTRAL-3 (NCT02201953) — Epclusa for the harder-to-treat genotype 3, about 95% cured (Foster et al, NEJM 2015).
  • ASTRAL-4 (NCT02201901) — Epclusa (with ribavirin) even in decompensated cirrhosis (Curry et al, NEJM 2015).
  • ASTRAL-5 (NCT02480712) — Epclusa in people living with both HIV and hepatitis C, about 95% cured.
  • ENDURANCE-1 (NCT02604017) — Mavyret for just 8 weeks matched 12 weeks, about 99% cured (Zeuzem et al, NEJM 2018).
  • EXPEDITION-8 (NCT03089944) — Mavyret 8 weeks in untreated people who already had compensated cirrhosis, 99.7% cured (Brown et al, J Hepatol 2020).
  • EXPEDITION-4 (NCT02651194) — Mavyret in advanced kidney disease and dialysis, about 98% cured.
  • POLARIS-1 (NCT02607735) — Vosevi rescued 96% of people whose earlier treatment failed (Bourliere et al, NEJM 2017).
  • POLARIS-4 (NCT02639247) — Vosevi salvage after other direct-acting antivirals, about 98% cured.
  • DORA (NCT03067129) — Mavyret shown safe and effective in children as young as 3 (Jonas et al, Hepatology 2021).
  • THINKER (NCT02743897) — kidneys from hepatitis-C-positive donors transplanted into people without hepatitis C, who were then cured (Reese et al, Ann Intern Med 2018).
  • HepNet Acute HCV-V (NCT03818308) — 8 weeks of Epclusa cured brand-new (acute) infection, supporting treat-early approaches.

Failed / De-adopted Therapies — what does NOT cure hepatitis C

You will encounter claims online. Here is an honest summary:

  • Interferon and ribavirin alone (the old standard): not de-adopted because it was useless — it cured some people — but it is now obsolete for almost everyone because it took up to a year, caused severe side effects, and cured fewer than half. Interferon is no longer recommended.
  • “Liver detoxes,” cleanses, and most supplements: do not cure hepatitis C. Milk thistle (silymarin), in particular, has been studied and does not clear the virus or reliably change liver outcomes — it is not a treatment.
  • High-dose vitamins, colloidal silver, ozone, and similar: no evidence of cure; some can harm the liver.
  • Stopping DAAs early because you “feel cured”: finishing the full course is what achieves cure; stopping early risks failure and resistance.
  • Herbal products can be dangerous, not just useless. Some herbal and “immune-boosting” supplements interact with DAAs (St. John’s wort lowers drug levels) or can themselves injure the liver. Always review supplements with your clinician. None is a substitute for standard care.
Bottom line: the only proven cure for hepatitis C is a course of direct-acting antiviral pills. If a product promises to “cure” or “flush” hepatitis C without DAAs, it is not telling the truth.

International Access & Regulatory Landscape (plain-language)

  • Same drugs, very different prices. Generic sofosbuvir-based regimens (made under licensing in India, Egypt, and elsewhere) have brought cure within reach in many lower-income countries, while wealthy countries historically paid high list prices that have since fallen.
  • Approvals are broadly aligned. Epclusa and Mavyret are approved by the U.S. FDA, the European EMA, Health Canada, the UK (with NICE guidance), Japan’s PMDA, and China’s NMPA, among others. Europe’s EASL guidance mirrors the U.S. pangenotypic, treat-everyone approach.
  • Some places have extra options. China has approved several home-grown DAAs not sold in the West; generic sofosbuvir/daclatasvir is widely used across Asia, Africa, and Latin America.
  • Restrictions are easing but not gone. Some health systems and insurers once limited treatment to people with advanced scarring or required sobriety; most such rules have been removed and are discouraged by guidelines, but a few remain — worth asking about where you live.
  • Whole countries are eliminating it. The World Health Organization aims to eliminate hepatitis C as a public-health threat by 2030; Egypt and Georgia have shown national elimination is achievable.
  • HCV: hepatitis C virus.
  • Acute / chronic: the first 6 months after infection / infection lasting beyond 6 months.
  • Antibody test: shows past exposure; stays positive after cure.
  • RNA / viral load test: shows whether the virus is active now; the test used to confirm infection and, later, reinfection.
  • Genotype: the “family” of the virus (1–6); rarely needed now.
  • DAA: direct-acting antiviral — the modern pills that cure HCV.
  • Pangenotypic: works against all six genotypes.
  • SVR12: sustained virologic response — no virus 12 weeks after treatment; the definition of cure.
  • Fibrosis (F0–F4): liver scarring, from none (F0) to cirrhosis (F4).
  • Cirrhosis: heavy, permanent scarring; “compensated” (still working) or “decompensated” (failing).
  • FibroScan: painless scan that measures liver stiffness to estimate scarring.
  • HCC: hepatocellular carcinoma — the main type of liver cancer.
  • Ascites: fluid buildup in the abdomen.
  • Hepatic encephalopathy: confusion/brain effects from a failing liver.
  • Varices: swollen veins (often in the esophagus) that can bleed.
  • Ribavirin: an older add-on medicine; causes anemia; unsafe in pregnancy.
  • Protease inhibitor / “previr” drugs: glecaprevir, voxilaprevir, grazoprevir — avoided in decompensated cirrhosis.
  • Harm reduction: practical steps (sterile supplies, naloxone, addiction treatment) that reduce harm without requiring abstinence.

Every hard number in this guide is tied to a named, dated source below, so you can check it yourself.

Guidelines & screening recommendations

  • AASLD/IDSA HCV Guidance — the living guideline at hcvguidelines.org, including the Simplified Treatment Algorithm and the 2025 Point-of-Care Test-and-Treat Algorithm.
  • USPSTF (2020) — grade B recommendation for one-time HCV screening of all adults 18 to 79.
  • CDC (2020) — MMWR guideline recommending universal one-time screening and screening in every pregnancy.
  • EASL Recommendations on Treatment of Hepatitis C — European guideline aligned with the pangenotypic, treat-everyone approach.
  • WHO (2022) guideline for the care and treatment of persons with chronic HCV, plus the WHO 2030 elimination strategy and 2024 hepatitis reports.

FDA labels & drug approvals

  • Epclusa (sofosbuvir/velpatasvir) — FDA label / prescribing information; first approved 2016.
  • Mavyret (glecaprevir/pibrentasvir) — FDA label / prescribing information; first approved 2017; 8-week naive indication and pediatric approval to age 3.
  • Vosevi (sofosbuvir/velpatasvir/voxilaprevir) — FDA label / prescribing information; approved 2017 for salvage.
  • Harvoni (ledipasvir/sofosbuvir) — FDA label / prescribing information; approved 2014.
  • Zepatier (elbasvir/grazoprevir) — FDA label / prescribing information; approved 2016.
  • Sovaldi (sofosbuvir) — FDA label / prescribing information; approved 2013 (the first all-oral backbone).
  • All DAA labels carry the HBV-reactivation boxed warning and the amiodarone–sofosbuvir bradycardia warning (per label).

Landmark clinical trials (with publication years)

  • ASTRAL-1 — Feld et al, NEJM 2015 (SOF/VEL, ~99% across genotypes).
  • ASTRAL-2 and ASTRAL-3 — Foster et al, NEJM 2015 (genotypes 2 and 3).
  • ASTRAL-4 — Curry et al, NEJM 2015 (decompensated cirrhosis trial).
  • ASTRAL-5 — Wyles et al, CID 2017 (HIV/HCV coinfection).
  • ENDURANCE-1 and ENDURANCE-3 — Zeuzem et al, NEJM 2018 (8 vs 12 weeks of GLE/PIB).
  • EXPEDITION-8 — Brown et al, J Hepatol 2020 (8 weeks in compensated cirrhosis, 99.7%).
  • EXPEDITION-4 — Gane et al, NEJM 2017 (severe kidney disease and dialysis).
  • POLARIS-1 and POLARIS-4 — Bourliere et al, NEJM 2017 (SOF/VEL/VOX salvage trial).
  • ION-1/2/3 — NEJM 2014 (ledipasvir/sofosbuvir program).
  • DORA — Jonas et al, Hepatology 2021 (pediatric trial to age 3).
  • THINKER — Reese et al, Ann Intern Med 2018 (hepatitis-C-positive-donor kidney trial).
  • MINMON (ACTG A5360) — Solomon et al, Lancet Gastroenterol Hepatol 2022 (minimal-monitoring trial).

Cost, access & tools

  • Gilead 2026 and AbbVie 2025 published wholesale acquisition costs (list prices) for Epclusa and Mavyret; Asegua authorized-generic pricing (2019 launch).
  • Inflation Reduction Act — Medicare Part D $2,000 annual out-of-pocket cap effective 2025.
  • Medicines Patent Pool generic licensing (2017 onward) underpinning low-cost sofosbuvir/velpatasvir in many countries.
  • University of Liverpool HEP Drug Interaction Checker (hep-druginteractions.org) and Hepatitis C Online (UW, hepatitisc.uw.edu), regularly updated through 2026.
Final word. Hepatitis C is one of modern medicine’s great success stories. If you have it, you can almost certainly be cured — usually with a short course of well-tolerated pills, often through your regular doctor, sometimes in a single visit. Get tested. If positive, get treated. And if you have cirrhosis, keep up the 6-month liver screening even after you’re cured.

This guide is educational and does not substitute for individualized medical advice. Treatment decisions depend on your specific situation and should be made with a qualified clinician. Evidence and access continue to evolve; verify specifics with your care team and current guidelines.

Clinical Trials — how to find them

Ask your care team whether a clinical trial is appropriate for your situation, and search ClinicalTrials.gov for current studies. See also the resources listed elsewhere in this guide.

Critical Safety Warning: Hepatitis B Reactivation

Direct-acting antiviral (DAA) therapy for hepatitis C (HCV) is highly effective, but it carries a critical and potentially fatal risk for people who have ever had hepatitis B (HBV) infection.

FDA Boxed Warning: Hepatitis B reactivation during HCV treatment with DAAs — potentially fatal:
Drug interactions with DAAs — important medication management: